• Incyte completed its acquisition of Vega Therapeutics, a Star Therapeutics subsidiary, adding Phase 3 von Willebrand disease antibody VGA039.
• Deal terms include USD 1.25 billion upfront. Star can receive up to USD 750 million tied to sales milestones.
• Incyte expects a one-time R&D expense in Q3 2026 results, with an impact also reflected in full-year 2026 reporting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260705825179) on July 06, 2026, and is solely responsible for the information contained therein.